# 20/20 Biolabs, Inc. (AIDX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $4M  
**Price:** $0.87 (+10.05%)

> 20/20 Biolabs, Inc. is a healthcare diagnostics company that develops and commercializes AI-powered, laboratory-based blood tests focused on early detection and prevention of cancers and chronic diseases. Its core offering is the OneTest for Cancer, a multi-cancer early detection blood test that uses machine learning and proteomic biomarkers to identify risk signals across several malignancies. The company also provides OneTest for Longevity, which measures inflammatory biomarkers to support assessment of long-term health risks, and offers convenient at-home sample collection through upper arm devices designed to avoid traditional needle-based draws. Testing is performed in its CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland, ensuring compliance with clinical laboratory quality standards. In addition, 20/20 Biolabs operates the Clinical Lab Innovation Axcelerator (CLIAx), supporting overseas diagnostics startups with a U.S.-based CLIA lab platform. Its portfolio further includes specialized tests such as PAULA’s Test and the BioCheck suspicious powder testing kit, serving occupational health, safety, and biodefense-related use cases. Founded in 2000 and headquartered in Gaithersburg, Maryland, the company occupies a niche at the intersection of artificial intelligence, proteomics, and clinical diagnostics.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2M | $604,541 | -$3M | -$4M | — |
| 2024 | $2M | $360,311 | -$6M | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $4M | $4M | -$19,225 | $1M | — |
| 2024 | $4M | $2M | $2M | $2M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$2M | — | — |
| 2024 | -$3M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/AIDX)